DEG sparks another recall
This article was originally published in The Tan Sheet
Executive Summary
Gilchrist & Soames, an Indianapolis-based provider of toiletries for the hotel market, initiated a worldwide voluntary recall of its Gilchrist & Soames 0.65 oz./18 mL toothpaste manufactured in China by Ming Fai Enterprises due to the presence of diethylene glycol in some samples of the product, FDA says Aug. 13. Hotels in the U.S. Canada, Mexico and other regions serviced by the firm's U.S. distribution center and hotels in the U.K., Ireland, Spain, France and other regions served by its U.K. distribution center have been asked to destroy remaining inventory. The DEG contamination was identified after the firm conducted a series of independent lab tests in response to an FDA alert June 1 about tainted toothpaste manufactured in China (1"The Tan Sheet" June 4, 2007, In Brief)...
You may also be interested in...
Applying Drug Model To Regulating Canada’s Supplements Sparks Opposition
A proposed amendment to Canada's Food and Drugs Act could move the regulation of natural health products closer to the pharmaceutical regulatory model, according to the Canadian Health Food Association
Chinese toothpaste import alert
FDA warns consumers not to use toothpaste labeled as made in China and issues an import alert June 1 to prevent toothpaste containing toxic diethylene glycol from entering the country. One shipment of toothpaste containing 3% DEG has been identified and detained at the U.S. border by agency inspectors, and DEG-containing toothpaste also was found at a distribution center and a retail store, FDA states. No U.S. incidents of poisoning from toothpaste adulterated with DEG have been reported, according to the agency. Panama's health ministry also recently found DEG in Chinese-manufactured toothpastes, which in part contributed to FDA's increased scrutiny of toothpaste and other dental products made in China, FDA says (1"The Tan Sheet" May 28, 2007, In Brief)...
US FDA’s Anti-Misinformation Campaigns Look Safer After Supreme Court Oral Arguments
FDA’s efforts to tackle misinformation may face fewer legal obstacles moving forward, following oral arguments at the Supreme Court on a case that could have broad ramifications for how the government communicates public health information.